We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Modulation of mRNA Activity Regulates Thrombin Synthesis

By LabMedica International staff writers
Posted on 23 Feb 2011
A paper described the molecular mechanism that regulates synthesis of thrombin, a protein required for blood clotting but also implicated in processes related to inflammation and tumor metastasis.

Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. More...
While prothrombin production increases when an organism experiences stress, the molecular pathways controlling this process have not been defined. Now, in a paper published in the February 4, 2011, issue of the journal Molecular Cell, investigators at the European Molecular Biology Laboratory (Heidelberg, Germany) have found that prothrombin expression is regulated by a posttranscriptional regulatory mechanism responding to stress and inflammation.

This mechanism is triggered by external stimuli that activate p38 MAPK (p38 mitogen-activated protein kinase), one of the class of mitogen-activated protein kinases that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

The activated p38 MAPK stimulates enzymes responsible for manipulating the 3′ end of certain classes of mRNA and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3′ end processing of mRNAs. By blocking this inhibitor, p38 MAPK removes an obstacle to thrombin synthesis, and the level of thrombin in the blood increases.

While elevated thrombin production is beneficial to an organism under stress, analysis of liver samples taken from septicemic mice and from cancer patients, revealed that thrombin production increased in response both to widespread inflammation during septicemia and to localized inflammation at the tumor's invasion front.

"Knowing the exact molecules involved, and how they act, has implications for treatment, especially as drugs that inhibit p38 MAPK are already being tested in clinical studies for other conditions,” said contributing author Dr. Matthias Hentze, associate director of the European Molecular Biology Laboratory. Those drugs could be good candidates for potential cancer or septicemia therapies.”

Related Links:

European Molecular Biology Laboratory




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.